Pediatrix Medical price target raised to $18.50 from $16.50 at UBS

UBS raised the firm’s price target on Pediatrix Medical (MD) to $18.50 from $16.50 and keeps a Neutral rating on the shares. Pediatrix Medican reported adjusted EBITDA ahead of consensus, with Q4 revenue $16M ahead of consensus, the analyst tells investors in a research note. UBS sees reduced downside to estimates as the company has completed its practice restructuring plan and is positioned to return focus to its core business.